EDP-420, a bicyclolide (bridged bicyclic macrolide), is active against Mycobacterium avium

Antimicrobial Agents and Chemotherapy

Volumn 51, Issue 5, 2007, Pages 1666-1670

  Bermudez, Luiz E ^a,b   Motamedi, Nima ^a   Chee, Christopher ^a   Baimukanova, Gyulnar ^a   Kolonoski, Peter ^a   Inderlied, Clark ^d   Aralar, Priscilla ^d   Wang, Guoqiang ^c   Ly, Tam Phan ^c   Young, Lowell S ^a  

^a Kuzell Institute for Arthritis and Infectious Diseases   (United States)

^b OREGON STATE UNIVERSITY   (United States)

^c Enanta Pharmaceuticals Inc   (United States)

^d CHILDREN S HOSPITAL LOS ANGELES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

9 ACETYLIMINO 3 DEHEXAPYRANOSYLOXY 9 DEOXO 3 OXO 6 O,11 O [2 [6 (1 PYRAZOLYL) 3 PYRIDINYLMETHOXYIMINO]PROPYLENE]ERYTHROMYCIN; CLARITHROMYCIN; MEFLOQUINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DISEASE PREDISPOSITION; DRUG ACTIVITY; EVALUATION; FEMALE; LIVER; MACROPHAGE; MOUSE; MYCOBACTERIOSIS; MYCOBACTERIUM AVIUM; NONHUMAN; PRIORITY JOURNAL; SPLEEN;

ANIMALS; ANTI-BACTERIAL AGENTS; BRIDGED COMPOUNDS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, BACTERIAL; FEMALE; HUMANS; MACROLIDES; MICE; MICE, INBRED C57BL; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM AVIUM;

EID: 34248384306     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.01303-06     Document Type: Article

References (24)

1. Aksamit, T. R. 2002. Mycobacterium avium complex pulmonary disease in patients with pre-existing lung disease. Clin. Chest Med. 23:643-653.
2. Benson, C. A., P. L. Williams, D. L. Cohn, S. Becker, P. Hojczyk, T. Nevin, J. A. Korvick, L. Heifets, C. C. Child, M. M. Lederman, R. C. Reichman, W. G. Powderly, G. F. Notario, B. A. Wynne, R. Hafner, et al. 2000. Clarithromycin or rifabutin alone or in combination for primary prophylaxis of Mycobacterium avium complex disease in patients with AIDS: a randomized, double-blind, placebo-controlled trial. J. Infect. Dis. 181:1289-1297.
3. Bermudez, L., C. B. Inderlied, P. Kolonoski, M. Wu, and L. S. Young. 1998. Activity of HMR3004 against Mycobacterium avium complex in vitro, in human macrophages and in beige mice. Clin. Microbiol. Infect. 4:325-331.
4. Bermudez, L. E., C. B. Inderlied, P. Kolonoski, M. Petrofsky, P. Aralar, M. Wu, and L. S. Young. 2001. Activity of moxifloxacin by itself and in combination with ethambutol, rifabutin, and azithromycin in vitro and in vivo against Mycobacterium avium. Antimicrob. Agents Chemother. 45:217-222.
5. Bermudez, L. E., C. B. Inderlied, P. Kolonoski, M. Wu, P. Aralar, and L. S. Young. 2001. Telithromycin is active against Mycobacterium avium in mice despite lacking significant activity in standard in vitro and macrophage assays and is associated with low frequency of resistance during treatment. Antimicrob. Agents Chemother. 45:2210-2214.
6. Bermudez, L. E., P. Kolonoski, M. Petrofsky, M. Wu, C. B. Inderlied, and L. S. Young. 2003. Mefloquine, moxifloxacin, and ethambutol are a triple-drug alternative to macrolide-containing regimens for treatment of Mycobacterium avium disease. J. Infect. Dis. 187:1977-1980.
7. Bermudez, L. E., P. Kolonoski, M. Wu, P. A. Aralar, C. B. Inderlied, and L. S. Young. 1999. Mefloquine is active in vitro and in vivo against Mycobacterium avium complex. Antimicrob. Agents Chemother. 43:1870-1874.
8. Bermudez, L. E., M. Petrofsky, P. Kolonoski, and L. S. Young. 1998. Emergence of Mycobacterium avium populations resistant to macrolides during experimental chemotherapy. Antimicrob. Agents Chemother. 42:180-183.
9. Carter, G., M. Wu, D. C. Drummond, and L. E. Bermudez. 2003. Characterization of biofilm formation by clinical isolates of Mycobacterium avium. J. Med. Microbiol. 52:747-752.
10. Carter, G., L. S. Young, and L. E. Bermudez. 2004. A subinhibitory concentration of clarithromycin inhibits Mycobacterium avium biofilm formation. Antimicrob. Agents Chemother. 48:4907-4910.
11. Casanova, J. L., and L. Abel. 2002. Genetic dissection of immunity to mycobacteria: the human model. Annu. Rev. Immunol. 20:581-620.
12. Chaisson, R. E., C. A. Benson, M. P. Dube, L. B. Heifets, J. A. Korvick, S. Elkin, T. Smith, J. C. Craft, F. R. Sattler, et al. 1994. Clarithromycin therapy for bacteremic Mycobacterium avium complex disease: a randomized, double-blind, dose-ranging study in patients with AIDS. Ann. Intern. Med. 121:905-911.
13. Chiu, J., J. Nussbaum, S. Bozzette, J. G. Tilles, L. S. Young, J. Leedom, P. N. Heseltine, J. A. McCutchan, et al. 1990. Treatment of disseminated Mycobacterium avium complex infection in AIDS with amikacin, ethambutol, rifampin, and ciprofloxacin. Ann. Intern. Med. 113:358-361.
14. Danelishvili, L., M. Wu, L. S. Young, and L. E. Bermudez. 2005. Genomic approach to identifying the putative target of and mechanisms of resistance to mefloquine in mycobacteria. Antimicrob. Agents Chemother. 49:3707-3714.
15. Dube, M. P., F. R. Sattler, F. J. Torriani, D. See, D. V. Havlir, C. A. Kemper, M. G. Dezfuli, S. A. Bozzette, A. E. Bartok, J. M. Leedom, J. G. Tilles, J. A. McCutchan, et al. 1997. A randomized evaluation of ethambutol for prevention of relapse and drug resistance during treatment of Mycobacterium avium complex bacteremia with clarithromycin-based combination therapy J. Infect. Dis. 176:1225-1232.
16. Flynn, J. L., and J. Chan. 2001. Immunology of tuberculosis. Annu. Rev. Immunol. 19:93-129.
17. Inderlied, C. B., L. S. Young, and J. K. Yamada. 1987. Determination of in vitro susceptibility of Mycobacterium avium complex isolates to antimycobacterial agents by various methods. Antimicrob. Agents Chemother. 31:1697-1702.
18. Nannini, E. C., M. Keating, P. Binstock, G. Samonis, and D. P. Kontoyiannis. 2002. Successful treatment of refractory disseminated Mycobacterium avium complex infection with the addition of linezolid and mefloquine. J. Infect. 44:201-203.
19. Prince, D. S., D. D. Peterson, R. M. Steiner, J. E. Gottlieb, R. Scott, H. L. Israel, W. G. Figueroa, and J. E. Fish. 1989. Infection with Mycobacterium avium complex in patients without predisposing conditions. N. Engl. J. Med. 321:863-868.
20. Scorneaux, B., A. Arya, A. Polemeropoulos, M. Lillard, F. Han, K. Amsler, A. J. Sonderfan, G. Wang, Y. C. Wang, Y. Peng, G. Xu, H. Kim, T. Lien, L. Phan, and Y. S. Or. 2003. In vitro and in vivo evaluation of EP-13420: a novel ketolide highly active against resistant pathogens and having exceptional pharmacokinetic properties in the dog. Abstr. 43rd Intersci. Conf. Antimicrob. Agents Chemother., abstr. F-1191.
21. Sullam, P. M., F. M. Gordin, B. A. Wynne, et al. 1994. Efficacy of rifabutin in the treatment of disseminated infection due to Mycobacterium avium complex. Clin. Infect. Dis. 19:84-86.
22. Tsuji, M., H. H. Miwa, M. Takema, E. Kanaoka, T. Yoshikawa, J. Shimada, and S. Kuwahara. 2005. Abstr. 45th Intersci. Conf. Antimicrob. Agents Chemother., abstr. F-2035.
23. Yamazaki, Y., L. Danelishvili, M. Wu, E. Hidaka, T. Katsuyama, B. Stang, M. Petrofsky, R. Bildfell, and L. E. Bermudez. 2006. The ability to form biofilm influences Mycobacterium avium invasion and translocation of bronchial epithelial cells. Cell. Microbiol. 8:806-814.
24. Young, L. S., L. Wiviott, M. Wu, P. Kolonoski, R. Bolan, and C. B. Inderlied. 1991. Azithromycin for treatment of Mycobacterium avium-intracellulare complex infection in patients with AIDS. Lancet 338:1107-1109.